# A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez

> **NCT06423573** · — · RECRUITING · sponsor: **Amryt Pharma** · enrollment: 580 (estimated)

## Conditions studied

- Epidermolysis Bullosa, Dystrophic
- Epidermolysis Bullosa, Junctional

## Interventions

- **DRUG:** Filsuvez

## Key facts

- **NCT ID:** NCT06423573
- **Lead sponsor:** Amryt Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2031-11-30
- **Final completion:** 2032-08-01
- **Target enrollment:** 580 (ESTIMATED)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423573, "A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06423573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*